The involvement of patients in regulatory discussions and measuring the needs of patients
Trial results of vemurafenib, cobimetinib and LDH as a predictive marker in BRAF-mutated melanoma
Ongoing and future melanoma trials
Newer oncogene addictions in NSCLC
A new standard of care for advanced lung cancer: what’s next for pembrolizumab?